Hepatitis C Virus
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Published in Medical Verdicts and Law Weekly, January 31st, 2008
Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with ribavirin as the market-leading treatment for patients with hepatitis C, in the United States and globally. Despite clear biases in the design of the "IDEAL" study that potentially favored patients taking Peg-Intron(TM) (peginterferon alfa-2b) regimens - particularly the ribavirin dose reduction protocol - the study results have shown that patients treated with a PEGASYS regimen had a similar chance of being successfully treated for hepatitis C.
"I do not expect that the results of the IDEAL study will meaningfully impact clinical...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- Agency for Healthcare Research & Quality
AHRQ Releases Consumer Financial Incentives Guide for Employers and Other Health Care Purchasers - American Lung Association
American Lung Association Announces Appointment of New Chief Operating Officer - AngioDynamics, Inc.
Court Denies Diomed Motion Against AngioDynamics - Attendance on Demand, Inc.
Web-Hosted Attendance on Demand(R) Introduces Innovative Web Time Clock - Autism
Thimerosal-Autism Link Rejected by Maryland Court - Bioscience
Bruker BioSciences Announces Filing of Definitive Proxy and Expiration of HSR Waiting Period for Planned Acquisition of Bruker BioSpin Group - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
